Jasper Therapeutics, Inc. announced that it has entered into a non-exclusive research collaboration with AVROBIO, Inc. to evaluate the use of JSP191, Jasper’s anti-CD117 monoclonal antibody, as a targeted conditioning agent option for patients with Fabry disease and/or Gaucher disease type 1.
[Jasper Therapeutics, Inc.]
7992332
{7992332:nan}
apa
50
1
168785
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
